Deborah Dunsire

The fourth CGRP mi­graine drug is here. Time for Lund­beck to prove it's worth $2B

They may be late, but Lund­beck is now of­fi­cial­ly in the game for pre­vent­ing mi­graine with CGRP drugs.

The FDA has OK’d eptinezum­ab, the prize in Lund­beck’s $2 bil­lion ac­qui­si­tion of Alder. Like ri­val of­fer­ings from Am­gen/No­var­tis, Eli Lil­ly and Te­va, the an­ti­body blocks the cal­ci­tonin gene-re­lat­ed pep­tide, which is be­lieved to di­late blood ves­sels in the brain and cause pain.

It will now be sold as Vyep­ti. The com­pa­ny has yet to an­nounce a price. Am­gen and No­var­tis had set the whole­sale ac­qui­si­tion cost of their pi­o­neer­ing Aimovig at $6,900 for a year’s sup­ply be­fore rais­ing it slight­ly this year; Lil­ly and Te­va had fol­lowed suit with Em­gal­i­ty and Ajovy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA